PRADA Project Introductory Session at Sunset Club, Karachi

PRADA Project Introductory Session at Sunset Club, Karachi

A productive Prescribing the Right Agent in Adults for Depression (PRADA) Trial Introductory Session was held on 5 September 2026, bringing together a diverse multidisciplinary group of stakeholders, including Postgraduate Psychiatry Trainees, Resident Medical Officers, Senior Medical Officers, General Practitioners, Psychiatrists, Psychologists, and Genomic Scientists.

The session introduced stakeholders to the PRADA trial, its objectives, and the PRADA tool. The PRADA team provided a practical demonstration of the tool, including how patient-reported information such as symptoms, symptom clusters, previous treatment experiences, and adverse effects is incorporated into the PRADA workflow, alongside the clinician-facing component of the tool.

The session was designed as an interactive stakeholder discussion group to understand potential barriers and facilitators to successful trial delivery, particularly in relation to participant recruitment, engagement, and retention. Clinicians also had the opportunity to explore the PRADA tool from a practical perspective and discuss how they would interact with and use the clinician-facing component during the trial. Discussions focused on the time required for clinicians to use the tool, how it could fit within their trial-related activities, potential workload considerations, and practical challenges that clinicians may experience when using PRADA as part of the study.

Stakeholders shared their experiences from clinical settings and provided valuable suggestions on how the research team could support clinicians in using the tool and participating effectively in the trial. These discussions will help the PRADA team anticipate practical challenges, refine recruitment and retention strategies, and ensure that the trial procedures are feasible and acceptable for both participants and clinicians.

Overall, the session provided an important opportunity for the PRADA team to engage directly with clinical and research stakeholders, gather practical feedback, and strengthen plans for the successful delivery of the ongoing PRADA trial.